B7-33 alternatives.
5 compounds compared to B7-33, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
B7-33 exists because native relaxin-2 is a two-chain, disulfide-linked hormone that is difficult and expensive to manufacture, and a single-chain 24-amino-acid mimetic is not. Its studied effects are anti-fibrotic, in cells and animals, across heart, kidney, lung, and vascular tissue. Anyone looking for an alternative has usually noticed the next line: it has never been tested in humans, has no approval, and is sold only as a research reagent labeled not for human consumption. There is no better-evidenced peptide acting through the relaxin receptor pathway. The compounds below overlap with B7-33 on tissue repair as a category, not on mechanism or on clinical proof.
B7-33 is an experimental single-chain peptide derived from the B-chain of the human hormone relaxin-2 (H2 relaxin).
- 01
- 02LarazotideC tierIn human trialsAT-1001 · larazotide acetate
Same category: healing & recovery. In human trials.
- 03Thymosin β-4D tierResearch / preclinical
Same category: healing & recovery. Research / preclinical.
- 04BPC-157D tierResearch / preclinicalbody protection compound
Same category: healing & recovery. Research / preclinical.
- 05TB-500F tierResearch / preclinicalthymosin β4 fragment
Same category: healing & recovery. Research / preclinical.
An “alternative” here means a compound that shares B7-33's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.